Mitochondrial DNA common deletion in cancer: Emerging evidence and methodological challenges
Computational and Structural Biotechnology Journal · 01.01.2025 · 27 · 3929-3940
DOI: 10.1016/j.csbj.2025.09.010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Computational and Structural Biotechnology Journal, online erschienen am 12.09.2025. Verfasst von Mun Kay Ho und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University Grants Committee Research Grants Council, Shenzen Municipal and Hong Kong Joint Innovation Project, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
The 4977 bp common deletion of the mitochondrial DNA (mtDNA-CD) is a large-scale deletion that has been frequently observed in various cancers in humans. The common deletion mutation affects 7 key genes encoding for several complex subunits essential to the mitochondrial oxidative phosphorylation system. In the last 20 years, the evidence for the presence of mtDNA-CD in cancer has been elusive. This review aims to examine the evidence of the molecular mechanism and prevalence of mtDNA-CD in different cancers, and to discuss methodological challenges in detecting the presence of mtDNA-CD from clinical samples, and the estimation of prevalence in cancers. This is an attempt to perform a comprehensive literature review and evaluation of experimental evidence to determine whether there is sufficient evidence to suggest a link between mtDNA-CD and cancer. Our results suggest there is a lack of evidence across all cancers. Source of potential discrepancies depends on the quality of the experimental methods, statistical analyses and sampling strategy. Emerging evidence indicates the presence of mtDNA-CD may be cell-type- and cancer-specific. With advances in experimental and analytical techniques, such as single cell genomic and transcriptomic sequencing, spatial omics profiling, and long-read sequencing, we expect to see more comprehensive research that can better clarify the role and prevalence of mtDNA-CD in cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China.
- Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong Special Administrative Region of China.
Förderung
- University Grants Committee Research Grants Council
- Shenzen Municipal and Hong Kong Joint Innovation Project
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangdong Provincial Natural Science Foundation
- Innovation and Technology Commission
Zitieren
APA
Ho, M. K., & Ho, J. W. K. (2025). Mitochondrial DNA common deletion in cancer: Emerging evidence and methodological challenges. Computational and Structural Biotechnology Journal, 27, 3929-3940. https://doi.org/10.1016/j.csbj.2025.09.010
Vancouver
Ho MK, Ho JWK. Mitochondrial DNA common deletion in cancer: Emerging evidence and methodological challenges. Computational and Structural Biotechnology Journal. 2025;27:3929-3940. doi:10.1016/j.csbj.2025.09.010
BibTeX
@article{Ho2025,
author = {Ho, Mun Kay and Ho, Joshua W K},
title = {Mitochondrial DNA common deletion in cancer: Emerging evidence and methodological challenges},
journal = {Computational and Structural Biotechnology Journal},
year = {2025},
volume = {27},
pages = {3929--3940},
doi = {10.1016/j.csbj.2025.09.010}
}
EUVIMED